Publication | Closed Access

Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance

Health SciencesCancer Drug ResistanceMedicineCancer GrowthEgfr InhibitorsAnti-cancer AgentAbcg2 Multidrug TransporterPharmacologyRadiation OncologyTumor MicroenvironmentCancer ResearchDrug DiscoveryDrug Resistance